Remibrutinib

Tier C — Watch / trade

Remibrutinib

Novartis

Originator

2025

First approval

Expiry (public)

$0.02B ▲

Peak sales

Small molecule

Type

Targets：BTK

Brand：Rhapsido

Indications (approved)：Chronic urticaria, Urticaria

Regional status

Approved

2025-09-30

Approved

2026-04-23

China

Approved

2025-11-25

Japan

Approved

2026-09-04

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield 2.80 g (LOU-064)

LOU-064-0015018-38-2LOU-064-0025018-41-7LOU-064-00338953-42-3LOU-064-00457561-39-4LOU-064-0051787294-51-2LOU-064-0061787294-47-6LOU-064-0071787294-52-3LOU-064-0081787294-54-5LOU-064-009502496-33-5LOU-064-0101418128-32-1LOU-064-0111418128-33-2LOU-064-0121613413-65-2LOU-064-013179232-29-2LOU-064-014411235-57-9API · Remibrutinib

Code	CAS No.	Intermediate
LOU-064-001	5018-38-2 Available	4,6-dichloro-5-methoxypyrimidine
LOU-064-002	5018-41-7 Available	6-chloro-5-methoxypyrimidin-4-amine
LOU-064-003	38953-42-3 Available	4-amino-6-chloropyrimidin-5-ol
LOU-064-004	57561-39-4 Available	tert-butyl (2-hydroxyethyl)(methyl)carbamate
LOU-064-005	1787294-51-2 Available	tert-butyl (2-((4-amino-6-chloropyrimidin-5-yl)oxy)ethyl)(methyl)carbamate
LOU-064-006	1787294-47-6 Available	4-cyclopropyl-2-fluoro-N-(5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide
LOU-064-007	1787294-52-3 Available	tert-butyl (2-((4-amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2-methylphenyl)pyrimidin-5-yl)oxy)ethyl)(methyl)carbamate
LOU-064-008	1787294-54-5 Available	N-(3-(6-amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide 2,2,2-trifluoroacetate
LOU-064-009	502496-33-5 Available	1-bromo-5-fluoro-2-methyl-3-nitrobenzene
LOU-064-010	1418128-32-1 Available	2-(5-fluoro-2-methyl-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
LOU-064-011	1418128-33-2 Available	5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
LOU-064-012	1613413-65-2 Available	methyl 4-cyclopropyl-2-fluorobenzoate
LOU-064-013	179232-29-2 Available	methyl 4-bromo-2-fluorobenzoate
LOU-064-014	411235-57-9 Available	cyclopropylboronic acid

Frequently asked questions

What are the approved indications of Remibrutinib?

Approved indications include: Chronic urticaria, Urticaria.

When does the Remibrutinib patent expire?

No public expiry year is available for Remibrutinib yet; this page updates once verified.

How many synthesis routes are recorded for Remibrutinib?

1 synthesis routes are recorded; the shortest is 10 steps with 2.80 g (LOU-064) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Remibrutinib intermediates?

14 intermediate CAS of Remibrutinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Remibrutinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22